These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 8375728

  • 1. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL, Reed E.
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [Abstract] [Full Text] [Related]

  • 2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV.
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [Abstract] [Full Text] [Related]

  • 3. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R, Kachhwaha VS.
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [Abstract] [Full Text] [Related]

  • 4. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH, Al Moundhri MS.
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [Abstract] [Full Text] [Related]

  • 5. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
    Yonezawa A, Inui K.
    Biochem Pharmacol; 2011 Mar 01; 81(5):563-8. PubMed ID: 21144842
    [Abstract] [Full Text] [Related]

  • 6. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C.
    Anticancer Res; 2000 Mar 01; 20(5C):3767-73. PubMed ID: 11268452
    [Abstract] [Full Text] [Related]

  • 7. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
    Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH.
    Cancer Treat Rep; 1981 Mar 01; 65(1-2):73-8. PubMed ID: 6784924
    [Abstract] [Full Text] [Related]

  • 8. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP, Buie LW, Savage SW.
    Ann Pharmacother; 2012 Feb 01; 46(2):276-81. PubMed ID: 22298599
    [Abstract] [Full Text] [Related]

  • 9. Nephrotoxicity of common drugs used by urologists.
    Bennett WM, Porter GA.
    Urol Clin North Am; 1990 Feb 01; 17(1):145-56. PubMed ID: 2407013
    [Abstract] [Full Text] [Related]

  • 10. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar 01; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

  • 11. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
    Matsuoka A, Ando Y.
    Gan To Kagaku Ryoho; 2017 Mar 01; 44(3):200-203. PubMed ID: 28292990
    [Abstract] [Full Text] [Related]

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 13. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
    Guo JH, Song ST, Xu ZL.
    Zhonghua Zhong Liu Za Zhi; 1994 Jan 01; 16(1):56-8. PubMed ID: 8033751
    [Abstract] [Full Text] [Related]

  • 14. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M, Barone R, Aghemo B, Mioli PR, De Simone M.
    Minerva Med; 2001 Aug 01; 92(4):207-11. PubMed ID: 11535965
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [About side effects of platinum drugs].
    Waszkiewicz K.
    Postepy Hig Med Dosw; 2001 Aug 01; 55(3):387-406. PubMed ID: 11505639
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 20. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
    Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K.
    Acta Med Okayama; 2018 Jun 30; 72(3):319-323. PubMed ID: 29926012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.